MindMed’s News Spree: Mescaline Trials, Chopra Foundation Partnership and LSD Research
MindMed (NASDAQ:MNMD) (NEO: MMED) released a series of new announcements following the company’s Q1 earnings report.
The company reported Thursday that it had obtained authorization from one of the local Swiss ethics committees to conduct its first clinical trial on mescaline.
The research is scheduled to begin in May at the University Hospital Basel Liechti Lab in Basel, Switzerland.
The study will examine the effects of various doses of mescaline and “the role of the serotonin 5-HT2A receptor in a mescaline-induced altered state of consciousness.”